One Year After Mild COVID-19: Emotional Distress but Preserved Cognition in Healthcare Workers.

ingentiumby ingentium

In Clinical Literature.

One Year After Mild COVID-19: Emotional Distress but Preserved Cognition in Healthcare Workers.

Publication date: Aug 25, 2025

Background/Objectives: Although COVID-19 may cause cognitive impairments for up to six months, the long-term effects of mild cases remain unclear. Given their high exposure and critical role in public health, assessing this impact on healthcare workers is essential. Aim: The present study aimed to examine the cognitive and emotional effects of mild COVID-19 in 92 healthcare workers one year after infection. Methods: In total, 50 had experienced mild COVID-19, while 42 had not been infected. Participants completed a neuropsychological assessment evaluating attention, memory, and executive functions, along with self-reported measures of anxiety, depression, post-traumatic stress, occupational stress, and burnout. Results: No significant cognitive differences were observed between the groups. However, both exhibited moderate-to-severe psychological distress, with the COVID-19 group showing higher trait anxiety (p = 0. 032). Emotional symptoms were significantly associated with neuropsychological performance-higher burnout (ρ from -0. 20 to -0. 28, p

Open Access PDF

Concepts Keywords
Covid cognition
Healthcare healthcare
Months long-term effects
Neuropsychological mild COVID-19
Pandemic neuropsychology

Semantics

Type Source Name
disease MESH COVID-19
disease MESH Emotional Distress
disease MESH cognitive impairments
disease IDO role
disease MESH infection
disease MESH anxiety
disease MESH depression
disease MESH stress occupational
disease MESH burnout
disease IDO symptom
disease MESH cough headache
disease MESH smell dysfunction
disease MESH encephalopathy
disease MESH myelitis
disease MESH seizures
disease MESH ischemic stroke
disease MESH viral infections
disease MESH intracranial hemorrhage
disease MESH neuroinflammation
disease IDO immune response
drug DRUGBANK Coenzyme M
disease MESH ‘brain fog
disease MESH disorientation
disease MESH memory deficits
disease MESH post traumatic stress disorder
disease MESH emotional disturbances
disease MESH professional burnout
disease MESH pneumonia
disease MESH hypoxia
disease IDO acute infection
disease MESH psychosis
disease MESH substance abuse
disease MESH Sore throat
disease MESH Conjunctivitis
disease MESH Dysgeusia
disease MESH Chest pain
disease MESH Syncope
disease MESH Aphasia
disease MESH Syndrome
disease MESH obsessions
disease MESH Emotional Exhaustion
disease IDO history
drug DRUGBANK Methionine
disease MESH psychological stress
disease MESH clinical relevance
disease MESH ‘long COVID
drug DRUGBANK Trestolone
drug DRUGBANK Pentaerythritol tetranitrate
drug DRUGBANK Etoperidone
disease MESH insomnia
disease MESH uncertainty
drug DRUGBANK Esomeprazole
drug DRUGBANK Indoleacetic acid
disease MESH feminization
disease MESH delayed memory
drug DRUGBANK Guanosine
drug DRUGBANK (S)-Des-Me-Ampa
disease MESH sequelae
drug DRUGBANK Carboxyamidotriazole
disease MESH emergency
disease MESH psychiatric disorders
disease MESH etiology
pathway REACTOME Methylation

Original Article

(Visited 6 times, 1 visits today)

Leave a Comment

Your email address will not be published. Required fields are marked *